Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

M. G. Kris; R. J. Gralla; D. P. Kelsen; E. S. Casper; M. T. Burke; J. J. Fiore; I. R. Cibas; R. T. Heelan

doi:10.1097/00000421-198510000-00007

Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

M. G. Kris, R. J. Gralla, D. P. Kelsen, E. S. Casper, M. T. Burke, J. J. Fiore, I. R. Cibas, R. T. Heelan

Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m² orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.

Original language	English (US)
Pages (from-to)	377-379
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	8
Issue number	5
DOIs	https://doi.org/10.1097/00000421-198510000-00007
State	Published - Jan 1 1985

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00000421-198510000-00007

Cite this

@article{f58f35d92bbc4eeca22170ea226fdb64,

title = "Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer",

abstract = "4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.",

author = "Kris, {M. G.} and Gralla, {R. J.} and Kelsen, {D. P.} and Casper, {E. S.} and Burke, {M. T.} and Fiore, {J. J.} and Cibas, {I. R.} and Heelan, {R. T.}",

year = "1985",

month = jan,

day = "1",

doi = "10.1097/00000421-198510000-00007",

language = "English (US)",

volume = "8",

pages = "377--379",

journal = "American Journal of Clinical Oncology",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

AU - Kris, M. G.

AU - Gralla, R. J.

AU - Kelsen, D. P.

AU - Casper, E. S.

AU - Burke, M. T.

AU - Fiore, J. J.

AU - Cibas, I. R.

AU - Heelan, R. T.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - 4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.

AB - 4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.

UR - http://www.scopus.com/inward/record.url?scp=0022358221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022358221&partnerID=8YFLogxK

U2 - 10.1097/00000421-198510000-00007

DO - 10.1097/00000421-198510000-00007

M3 - Article

C2 - 3864366

AN - SCOPUS:0022358221

SN - 0277-3732

VL - 8

SP - 377

EP - 379

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

IS - 5

ER -

Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this